Hella Luksch1, W Alexander Stinson2, Derek J Platt3, Wei Qian4, Gowri Kalugotla4, Cathrine A Miner4, Brock G Bennion2, Alexander Gerbaulet5, Angela Rösen-Wolff6, Jonathan J Miner7. 1. Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 2. Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Mo. 3. Department of Molecular Microbiology, Washington University School of Medicine, St Louis, Mo. 4. Department of Medicine, Washington University School of Medicine, St Louis, Mo. 5. Institute for Immunology, Technische Universität Dresden, Dresden, Germany. 6. Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. Electronic address: Angela.Roesen-Wolff@uniklinikum-dresden.de. 7. Department of Medicine, Washington University School of Medicine, St Louis, Mo; Department of Pathology and Immunology, Washington University School of Medicine, St Louis, Mo; Department of Molecular Microbiology, Washington University School of Medicine, St Louis, Mo. Electronic address: jonathan.miner@wustl.edu.
Abstract
BACKGROUND: Monogenic interferonopathies are thought to be mediated by type I interferon. For example, a gain-of-function mutation in stimulator of interferon genes (STING; N153S) upregulates type I interferon-stimulated genes and causes perivascular inflammatory lung disease in mice. The equivalent mutation in human subjects also causes lung disease, which is thought to require signaling through the cyclic GMP-AMP synthase (cGAS)-STING pathway and subsequent activation of interferon regulatory factors (IRFs) 3 and 7, type I interferon, and interferon-stimulated genes. OBJECTIVE: We set out to define the roles of cGAS, IRF3, IRF7, the type I interferon receptor (IFN-α and IFN-β receptor subunit 1 [IFNAR1]), T cells, and B cells in spontaneous lung disease in STING N153S mice. METHODS: STING N153S mice were crossed to animals lacking cGAS, IRF3/IRF7, IFNAR1, adaptive immunity, αβ T cells, and mature B cells. Mice were evaluated for spontaneous lung disease. Additionally, bone marrow chimeric mice were assessed for lung disease severity and survival. RESULTS: Lung disease in STING N153S mice developed independently of cGAS, IRF3/IRF7, and IFNAR1. Bone marrow transplantation revealed that certain features of STING N153S-associated disease are intrinsic to the hematopoietic compartment. Recombination-activating gene 1 (Rag1)-/- STING N153S mice that lack adaptive immunity had no lung disease, and T-cell receptor β chain (Tcrb)-/- STING N153S animals only had mild disease. STING N153S led to a reduction in percentages and numbers of naive and regulatory T cells, as well as an increased frequency of cytokine-producing effector T cells. CONCLUSION: Spontaneous lung disease in STING N153S mice develops independently of type I interferon signaling and cGAS. STING N153S relies primarily on T cells to promote lung disease in mice.
BACKGROUND: Monogenic interferonopathies are thought to be mediated by type I interferon. For example, a gain-of-function mutation in stimulator of interferon genes (STING; N153S) upregulates type I interferon-stimulated genes and causes perivascular inflammatory lung disease in mice. The equivalent mutation in human subjects also causes lung disease, which is thought to require signaling through the cyclic GMP-AMP synthase (cGAS)-STING pathway and subsequent activation of interferon regulatory factors (IRFs) 3 and 7, type I interferon, and interferon-stimulated genes. OBJECTIVE: We set out to define the roles of cGAS, IRF3, IRF7, the type I interferon receptor (IFN-α and IFN-β receptor subunit 1 [IFNAR1]), T cells, and B cells in spontaneous lung disease in STING N153Smice. METHODS: STING N153Smice were crossed to animals lacking cGAS, IRF3/IRF7, IFNAR1, adaptive immunity, αβ T cells, and mature B cells. Mice were evaluated for spontaneous lung disease. Additionally, bone marrow chimeric mice were assessed for lung disease severity and survival. RESULTS:Lung disease in STING N153Smice developed independently of cGAS, IRF3/IRF7, and IFNAR1. Bone marrow transplantation revealed that certain features of STING N153S-associated disease are intrinsic to the hematopoietic compartment. Recombination-activating gene 1 (Rag1)-/- STING N153Smice that lack adaptive immunity had no lung disease, and T-cell receptor β chain (Tcrb)-/- STING N153S animals only had mild disease. STING N153S led to a reduction in percentages and numbers of naive and regulatory T cells, as well as an increased frequency of cytokine-producing effector T cells. CONCLUSION:Spontaneous lung disease in STING N153Smice develops independently of type I interferon signaling and cGAS. STING N153S relies primarily on T cells to promote lung disease in mice.
Authors: P Mombaerts; A R Clarke; M A Rudnicki; J Iacomini; S Itohara; J J Lafaille; L Wang; Y Ichikawa; R Jaenisch; M L Hooper Journal: Nature Date: 1992-11-19 Impact factor: 49.962
Authors: Marieke A G Essers; Sandra Offner; William E Blanco-Bose; Zoe Waibler; Ulrich Kalinke; Michel A Duchosal; Andreas Trumpp Journal: Nature Date: 2009-02-11 Impact factor: 49.962
Authors: Dara L Burdette; Kathryn M Monroe; Katia Sotelo-Troha; Jeff S Iwig; Barbara Eckert; Mamoru Hyodo; Yoshihiro Hayakawa; Russell E Vance Journal: Nature Date: 2011-09-25 Impact factor: 49.962
Authors: Brock G Bennion; Carys A Croft; Teresa L Ai; Wei Qian; Amber M Menos; Cathrine A Miner; Marie-Louis Frémond; Jean-Marc Doisne; Prabhakar S Andhey; Derek J Platt; Jennifer K Bando; Erin R Wang; Hella Luksch; Thierry J Molina; Elisha D O Roberson; Maxim N Artyomov; Angela Rösen-Wolff; Marco Colonna; Frédéric Rieux-Laucat; James P Di Santo; Bénédicte Neven; Jonathan J Miner Journal: Cell Rep Date: 2020-06-16 Impact factor: 9.423
Authors: Kevin MingJie Gao; Mona Motwani; Thomas Tedder; Ann Marshak-Rothstein; Katherine A Fitzgerald Journal: Proc Natl Acad Sci U S A Date: 2022-06-13 Impact factor: 12.779